Faculty Profiles - ANDO Yuichi

Papers - ANDO Yuichi

Division display 1 - 20 of about 124 ／ All the affair displays >>

Ando, Y; Terada, T

JOURNAL OF CLINICAL ONCOLOGY Vol. 41 ( 22 ) page： 3875 - + 2023.8

Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Ando, Y; Nishiyama, H; Shimodaira, H; Takano, N; Sakaida, E; Matsumoto, K; Nakanishi, K; Sakai, H; Tsukamoto, S; Komine, K; Yasuda, Y; Kato, T; Fujiwara, Y; Koyama, T; Kitamura, H; Kuwabara, T; Yonezawa, A; Okumura, Y; Yakushijin, K; Nozawa, K; Goto, H; Matsubara, T; Hoshino, J; Yanagita, M

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY Vol. 28 ( 10 ) page： 1315 - 1332 2023.10

A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan

Matsuoka, A; Shimazu, T; Takahashi, M; Nagashima, F; Nishiyama, H; Fujimori, M; Ando, Y

JOURNAL OF GERIATRIC ONCOLOGY Vol. 14 ( 1 ) page： 101399 2023.1

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal

Ando, Y; Morita, S; Shimokata, T; Tsuzuki, T; Inafuku, S; Iwami, K; Brega, N; Akagawa, T; Tsujino, T; Ogawa, T

INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 11 ( 4 ) page： 242 - 246 2022.10

Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors.

Liang Y, Maeda O, Nishida K, Chretien B, Ando Y

Cancer science 2025.1

UGT1A1 Testing for the Risk of Nanoliposomal Irinotecan-Related Toxicity

Liang, Y; Ando, Y

JOURNAL OF CLINICAL ONCOLOGY Vol. 43 ( 3 ) page： 357 2025.1

Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors.

Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Koshiyama Y, Yasuda S, Toyoda H, Ando Y, Shimoyama Y, Kawashima H

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2025.1

Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease

Inukai, Y; Ito, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Shimizu, T; Hattori, M; Takeyama, T; Ando, Y; Nishikawa, T; Morita, K; Toyoda, H; Ishigami, M; Kawashima, H

JOURNAL OF DIGESTIVE DISEASES Vol. 25 ( 11-12 ) page： 685 - 693 2025.1

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team

Ito, T; Mizuno, K; Yamamoto, T; Yasuda, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Hama, M; Kataoka, T; Shimokata, T; Ando, Y; Kawashima, H

HEPATOLOGY RESEARCH Vol. 54 ( 11 ) page： 1060 - 1069 2024.11

Greeting from the new editor-in-chief

Ando, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 86 ( 4 ) page： 536 - 537 2024.11

A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy

Liang, Y; Maeda, O; Miyata, K; Tanaka, C; Kanda, M; Shimizu, D; Fukaya, M; Koike, M; Kodera, Y; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 20 ( 5 ) page： 661 - 667 2024.10

Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older

Yagishita, S; Yamanaka, Y; Kurata, T; Watanabe, K; Hosomi, Y; Horinouchi, H; Ohe, Y; Nakahara, Y; Naoki, K; Asao, T; Takahashi, K; Saeki, S; Sakagami, T; Nakashima, K; Tsubata, Y; Fujita, Y; Wakui, H; Furuta, M; Konishi, JS; Ohuchi, M; Ando, Y; Mizugaki, H; Hamada, A

CLINICAL PHARMACOLOGY & THERAPEUTICS Vol. 116 ( 4 ) page： 1042 - 1051 2024.10

Chemotherapy for metastatic or recurrent soft tissue sarcoma: real-world experience in a single institute

Maeda, O; Shimokata, T; Mitsuma, A; Urakawa, H; Takano, Y; Kondo, C; Furune, S; Miyai, Y; Torii, N; Liang, Y; Morita, S; Inoue, M; Ando, Y

ANNALS OF ONCOLOGY Vol. 35 page： S1349 - S1349 2024.10

Outcomes of immune-related liver injury managed by hepatologists in a multidisciplinary toxicity team

Ito, T; Mizuno, K; Yamamoto, T; Hama, M; Kataoka, T; Shimokata, T; Kawashima, H; Ando, Y

ANNALS OF ONCOLOGY Vol. 35 page： S1342 - S1343 2024.10

FEVER AFTER THE ADMINISTRATION OF ATEZOLIZUMAB AND BEVACIZUMAB PREDICTS LIVER INJURY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A PROSPECTIVE OBSERVATIONAL ANALYSIS USING A MULTIPLEX BEAD-BASED IMMUNOASSAY

Ito, T; Yamamoto, T; Nishida, K; Kobayashi, Y; Mizuno, K; Yokoyama, S; Imai, N; Ishizu, Y; Honda, T; Ishigami, M; Koya, T; Nakashima, S; Naito, T; Yasuda, S; Kuzuya, T; Toyoda, H; Ando, Y; Yoshio, S; Kawashima, H

HEPATOLOGY Vol. 80 2024.10

Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study

Okuji, T; Iwama, S; Kobayashi, T; Yasuda, Y; Ito, M; Yamagami, A; Ando, M; Hase, T; Shibata, H; Hatta, T; Zhou, X; Onoue, T; Kawaguchi, Y; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Ando, Y; Hashimoto, N; Arima, H

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 86 ( 3 ) page： 452 - 463 2024.8

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma

Liang, Y; Maeda, O; Kondo, C; Nishida, K; Ando, Y

PLOS ONE Vol. 19 ( 7 ) page： e0307580 2024.7

Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.

Kato T, Kawaguchi T, Funakoshi T, Fujiwara Y, Yasuda Y, Ando Y

Cancer diagnosis & prognosis Vol. 4 ( 4 ) page： 390 - 395 2024.7

Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAFV600E mutation

Takano, Y; Shimokata, T; Urakawa, H; Kikumori, T; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 13 ( 3 ) page： 209 - 213 2024.7

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

Kobayashi, T; Iwama, S; Yamagami, A; Izuchi, T; Suzuki, K; Otake, K; Yasuda, Y; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Nishio, N; Mori, S; Shimokata, T; Sano, T; Niimi, K; Yoshikawa, N; Akamatsu, S; Ando, Y; Akiyama, M; Sone, M; Ishii, M; Arima, H

CANCER IMMUNOLOGY IMMUNOTHERAPY Vol. 73 ( 8 ) page： 146 2024.6

　 PREV - NEXT 　

<ANDO Yuichi>

Papers - ANDO Yuichi